Autres langues Madrigal Pharmaceuticals, Inc.

Actions

MDGL

US5588681057

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
534,40 ^USD	+1,00%		+0,24%	-8,23%

14/09	Madrigal Pharmaceuticals, Inc. annonce l'ouverture de son nouveau siège social à Conshohocken, en Pennsylvanie	CI
10/09	Transcript : Madrigal Pharmaceuticals, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 01:00 PM

Autres langues

16/09	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
14/09	Madrigal Pharmaceuticals, Inc. Announces Opening New Headquarters in Conshohocken, Pa
02/09	Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
20/08	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
12/08	Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
12/08	Madrigal Pharmaceuticals, Inc. Announces Appointment of John C. Reed as Board Director
06/08	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
06/08	Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
30/07	Madrigal Pharmaceuticals Q2 Loss Widens, Revenue Increases
30/07	Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q2 Net Loss $1.99 a Share, vs. FactSet Est of $2.68 Loss
30/07	Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $364.3M, vs. FactSet Est of $352.1M
30/07	Madrigal: Q2 Earnings Snapshot
30/07	Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
21/07	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/07	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,368,253, According to a Recent SEC Filing
16/07	Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
13/07	Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says
13/07	Madrigal Pharmaceuticals Expands Rezdiffra Patent Protection With Three New Patents
13/07	Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
06/07	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
02/07	Suzhou Ribo Life Science Achieves First Candidate Drug Nomination Milestone in Sirna Partnership with Madrigal
02/07	Suzhou Ribo Life Science, Madrigal Pharma Reach Milestone for Liver Disease Treatment
29/06	Madrigal Pharmaceuticals, Inc.(NasdaqGS:MDGL) dropped from Russell 2000 Index
29/06	Madrigal Pharmaceuticals, Inc.(NasdaqGS:MDGL) added to Russell Midcap Growth Benchmark